Endostatin serum level in acute myeloid leukemia

Neoplasma

Volumn 52, Issue 2, 2005, Pages 182-184

  Wrobel T ^a   Mazur, G ^a   Kapelko, K ^a   Kuliczkowski, K ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Acute myeloid leukemia; Angiogenesis; Endostatin

Indexed keywords

ENDOSTATIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANGIOGENESIS; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER REGRESSION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SOLID TUMOR;

EID: 17044415996     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. AGUAYO A, ESTEY E, KANTARIJAN H, MANSOURI T, GIDEL C et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94: 3717-3721.
2. BERTOLINI F, PAOLUCCI M, PECCATORI F, CINIERI S, AGAZZI A et al. Angiogenic growth factors end endostatin in ino-Hodgkin's lymphoma. Br J Haematol 1999; 106: 504-509.
3. BERTOLINI F, FUSETTI L, MANCUSO P, GOBBI A, CORSINI C et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood 2000; 96: 282-287.
4. BRUSERUD O, GLENJEN N, RYNINGEN A. Effects of angiogenic regulators on in vitro proliferation and cytokine secretion by native human acute myelogenous leukemia blasts. Eur J Haematol 2003; 71: 9-17.
5. FOLKMAN J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
6. FOLKMAN J. Cancer without disease. Nature 2004; 427: 787-789.
7. GLENJEN N, MOSEVOLL KA, BRUSERUD O. Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. Int J Cancer 2002; 101: 86-94.
8. GORA-TYBOR J, BLONSKI JZ, ROBAK T. Circulating pro-angiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators of Inflammation 2003; 12: 167-171.
9. HUSSONG JW, RODGERS GM, SHAMI PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309-313.
10. JUNG SP, SIEGRIEST B, HORNICK CA, WANG YZ, WADE MR et al. Effect of human recombinant endostatin protein on human angiogenesis. Angiogenesis 2002; 5: 111-118.
11. KUMAR S, WITZIG T, TIMM M, HAUG J, WELLIK J, KIMLINGER TK et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: Evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004 May 6 [Epub ahead of print].
12. LAI R, ESTEY E, SHEN Y, DESPA S, KANTARIJAN H ET AL. Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer 2002; 94: 14-17.
13. LIU TC, PENG CT, LIN SF, CHANG CS, CHEN TP, CHANG JG. Association of endostatin D104N with leukemia. Kaohsiung J Med Sci 2003; 19: 1-5.
14. LOVENBERG B, DOWNING JR, BURNETT A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
15. O'REILLY MS, BOEHM T, SHING Y, FUKAI N, VASIOS G et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 1-20.
16. SCHUCH G, HEYMACH JV, NOMI M, MACHLUF M, FORCE J et al. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 2003; 63: 8345-8350.
17. TEH SH, HILL AD, LEE AW, FOLEY D, KENNEDY S et al. Raised plasma endostatin leves correlate inversely with breast cancer angiogenesis. J Surg Res 2004; 116: 165-171.